Arrowstreet Capital
TBPH icon

Arrowstreet Capital’s Theravance Biopharma TBPH Stock Holding History

Arrowstreet Capital’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-327,546
Closed -$5.32M – 2123
2026
Q1 		$5.32M Sell
327,546
-635,711
-66% -$11.2M ﹤0.01% 1143
2025
Q4 		$18M Buy
963,257
+236,474
+33% +$3.92M 0.01% 769
2025
Q3 		$10.6M Buy
+726,783
New +$9.18M 0.01% 940
2025
Q2 		– Sell
-221,469
Closed -$1.98M – 2084
2025
Q1 		$1.98M Buy
+221,469
New +$2.06M ﹤0.01% 1300
2015
Q1 		– Sell
-18,431
Closed -$275K – 1220
2014
Q4 		$275K Buy
+18,431
New +$321K ﹤0.01% 1147

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Arrowstreet Capital's TBPH Position: Q2 2026 in Review

Arrowstreet Capital sold out of Theravance Biopharma (TBPH) in Q2 2026, closing a stake of 327,546 shares — an estimated $5.32M sold.

Arrowstreet Capital first reported a position in TBPH in Q4 2014 and held it in 5 quarters. The position peaked at $18M in Q4 2025. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Arrowstreet Capital reported no remaining Theravance Biopharma position as of Q2 2026 after selling out during the quarter.
  • Arrowstreet Capital sold 327,546 Theravance Biopharma shares in Q2 2026, an estimated $5.32M.
  • Arrowstreet Capital first reported a position in Theravance Biopharma in Q4 2014 and held it in 5 quarters.
  • Arrowstreet Capital's Theravance Biopharma position peaked at $18M in Q4 2025.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.